Category: CD47

  • Gilead cleared to restart trials of CD47 drug magrolimab

    Gilead Sciences can restart pivotal trials of its cancer antibody magrolimab – the centre piece of its $4.9 billion acquisition of Forty Seven in 2020 – after the FDA relaxed its partial clinical hold on the studies. The US regulator implemented the restrictions on trials of magrolimab given in combination with Bristol-Myers Squibb’s Vidaza (azacitidine) […]

  • Pfizer vaults into CD47 arena, buying Trillium for $2.3 billion

    Pfizer is the latest big pharma company to take a position on drugs that target CD47 – a ‘don’t eat me’ signal that protects cancer cells from being attacked by the immune system. The drugmaker has agreed a $2.3 billion deal to buy Canadian biotech Trillium Therapeutics and its two lead candidates – TTI-622 and […]

  • 2nd Macrophage-directed Therapies Summit

    Harnessing the Potential of Macrophage Therapies Using Small Molecule, Antibody & Cell Therapy based Approaches for Oncology and Beyond The $4.9 billion acquisition of Forty Seven by Gilead is an example of the explosive excitement and investment into macrophage-directed therapies, utilizing CD47 checkpoint blockades, repolarization approaches and engineered macrophages, that we have witnessed in recent […]